title: Evaluation of monolithic osmotic tablet system for nifedipine delivery in vitro and in vivo.
abstract: The aim of this study was to evaluate the monolithic osmotic tablet system (MOTS) containing a solid dispersion with the practically water-insoluble drug nifedipine in vitro and in vivo. In the drug release study in vitro, the release profiles of this system had almost zero-order kinetics. The influences of tablet formulation variables, sizes of the delivery orifice, membrane variables, and values of pH in the dissolution medium on nifedipine release from MOTS have been investigated. The results provided evidence that the tablet core played an important role in MOTS. While orifice sizes and membrane variables affected the nifedipine release rate, MOTS was independent of the dissolution medium. The appropriate orifice size was found to be in the range of 0.5-1.0 mm. The coating membrane incorporating hydrophilic polyethylene glycol (PEG) formed a porous structure. The human pharmacokinetics and relative bioavailability of MOTS containing nifedipine were compared with a commercial Adalat osmotic tablet system containing an equivalent dose of nifedipine following an oral single dose of 30 mg given to each of 11 healthy volunteers in an open, randomized crossover study in vivo. The relative bioavailability for MOTS was 112%. There was no statistically significant difference in the pharmacokinetic parameters between two dosage forms. It is concluded that the monolithic osmotic tablet controlled release system is feasible for a long-acting preparation as a once-daily treatment.
authors.affiliation: School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning, P.R. China.
authors.forename: Xing
authors.initials: X
authors.lastname: Liu
authors.forename: Dawei
authors.initials: D
authors.lastname: Chen
authors.forename: Ruhua
authors.initials: R
authors.lastname: Zhang
mesh_terms: D000328:Adult; D002851:Chromatography, High Pressure Liquid; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006801:Humans; D008297:Male; D009543:Nifedipine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D009995:Osmosis / Q000187:drug effects; D013607:Tablets / Q000008:administration & dosage / Q000493:pharmacokinetics; D013678:Technology, Pharmaceutical / Q000379:methods*; D013997:Time Factors
chemical_list: D003692:Delayed-Action Preparations; D013607:Tablets; D009543:Nifedipine